Abstract

Type-1 Diabetes Mellitus (T1DM) is an autoimmune condition characterized by the destruction of pancreatic β-cells, leading to lifelong insulin dependence. Recent advances in understanding the role of inflammation and immune dysregulation in T1DM pathogenesis have provided new insights into its etiology and potential therapeutic targets. This article reviews the current understanding of how inflammation and immune system abnormalities contribute to the development of T1DM and discusses emerging therapeutic approaches aimed at modulating these processes. By exploring these mechanisms, this review aims to highlight strategies for improving disease management and advancing treatment options.